Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
McKinsey
Boehringer Ingelheim
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

NATROBA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Natroba, and when can generic versions of Natroba launch?

Natroba is a drug marketed by Parapro Llc and is included in one NDA. There are three patents protecting this drug.

This drug has forty-eight patent family members in thirty countries.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the spinosad profile page.

Drug patent expirations by year for NATROBA
Drug Prices for NATROBA

See drug prices for NATROBA

Drug Sales Revenue Trends for NATROBA

See drug sales revenues for NATROBA

Recent Clinical Trials for NATROBA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AccelovancePhase 3
ParaPRO LLCPhase 3
ParaPRO LLCPhase 4

See all NATROBA clinical trials

Pharmacology for NATROBA
Drug ClassPediculicide
Synonyms for NATROBA
Comfortis
EC 434-300-1
NaturaLyte
Spinosad [USAN]
UNII-XPA88EAP6V
XDE 105
XPA88EAP6V

US Patents and Regulatory Information for NATROBA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for NATROBA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0375316 SPC/GB02/028 United Kingdom   Start Trial PRODUCT NAME: SPINOSAD; REGISTERED: CH W 6020 20010313; UK 0714 20020227
0375316 C350009 Netherlands   Start Trial PRODUCT NAME: SPINOSAD, DESGEWENST IN DE VORM VAN EEN ZOUT; NATL. REGISTRATION NO/DATE: 12363 N 20020913; FIRST REGISTRATION: SE 4511 20020204
0375316 06C0047 France   Start Trial PRODUCT NAME: SPINOSAD; REGISTRATION NO/DATE IN FRANCE: 2060098 DU 20060628; REGISTRATION NO/DATE AT EEC: 9275/B DU 20011023
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Johnson and Johnson
Baxter
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.